Year: 2013
Type: review
Abstract: Acute myocardial infarction (MI) is a major cause of death and disability worldwide. In patients with MI, the treatment of choice for reducing acute myocardial ischemic injury and limiting MI size is timely and effective myocardial reperfusion using either thombolytic therapy or primary percutaneous coronary intervention (PPCI). However, the process of reperfusion can itself induce cardiomyocyte death, known as myocardial reperfusion injury, for which there is still no effective therapy. A number of new therapeutic strategies currently under investigation for preventing myocardial reperfusion injury have the potential to improve clinical outcomes in patients with acute MI treated with PPCI.
DOI: 10.1172/jci62874
Authors: Derek J. Hausenloy, Derek M. Yellon
Institution: University College London
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: Exosomes - circulating cardioprotective nanoparticles, G3688806800, RENEWAL: Protection of the ischaemic and reperfused heart: investigation of basic mechanisms and therapeutic potential in animal and human myocardium, NIHR Senior Investigator Award, The interplay between survival kinases and the mitochondrial permeability transition pore: its role in ischaemic preconditioning and postconditioning
OpenAlex ID: W2051395985